<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671719</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_0628</org_study_id>
    <nct_id>NCT04671719</nct_id>
  </id_info>
  <brief_title>Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities</brief_title>
  <acronym>GNAS-AUTAX</acronym>
  <official_title>Autotaxin in Patients With GNAS/PTH Abnormalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PTH secretion defects (grouped under the name hypoparathyroidism) are due to abnormalities in&#xD;
      the PTH gene, abnormalities in the development of the parathyroid glands which synthesize PTH&#xD;
      or abnormalities of the calcium sening receptor whose role is to adapt PTH level to ambient&#xD;
      calcium level.&#xD;
&#xD;
      In contrast, primary hyperparathyroidism in children is also exceptional; expressed by&#xD;
      hypercalcemia, with a renal and bon risk.&#xD;
&#xD;
      Pseudo-hypoparathyroidism, now known under the term inactivating PTH / PTHrP Signaling&#xD;
      Disorder or iPPSD, are rare pathologies characterized by resistance to the action of PTH&#xD;
      sometimes associated with other symptoms, in particular chondrodysplasia. They are linked to&#xD;
      a defect in the action of a factor in the signaling pathway of G protein-coupled receptors&#xD;
      that activate the production of cyclic AMP (cAMP). IPPSDs are most often due to a molecular&#xD;
      defect in the GNAS gene, subject to parental imprint.&#xD;
&#xD;
      Fibrous dysplasia / McCune-Albright syndrome is a rare disease caused by somatic&#xD;
      &quot;gain-of-function&quot; mutations in the GNAS gene located on chromosome 20q13 leading to&#xD;
      activation of the protein Gαs and inappropriate production of intracellular cyclic adenosine&#xD;
      monophosphate (cAMP). The clinical phenotype is determined by the location and extent of the&#xD;
      tissues affected by this mutation.&#xD;
&#xD;
      Autotaxin (ATX) is a protein secreted by different tissues including the liver, fatty tissue,&#xD;
      and bone. Today, ATX is described as the major source of LPA in the bloodstream. LPA&#xD;
      interacts with one of its receptors on the surface of the cell membrane. Depending on the&#xD;
      receptor engaged, one or more Gα subunits (G12 / 13, GQ, Gi / o or Gs) will activate multiple&#xD;
      cell signaling pathways.&#xD;
&#xD;
      In bone, ATX is expressed by osteoclasts and osteoblasts. Recent laboratory data have shown&#xD;
      that PTH stimulates ATX expression in osteoblasts in a dose-dependent manner.&#xD;
&#xD;
      The objective of this study is to provide clinical proof of concept that the PTH / Gαs / ATX&#xD;
      pathway is truly significant in physiology and pathology, by studying the full spectrum of&#xD;
      PTH and GNAS pathologies. If this proof of concept is obtained, therapeutic applications will&#xD;
      probably be possible in the long term.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">March 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of circulating autotaxin</measure>
    <time_frame>At inclusion</time_frame>
    <description>Concentration of circulating autotaxin measured in patient serum by ELISA assay</description>
  </primary_outcome>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Fibrous Dysplasia</condition>
  <condition>Albright Syndrome</condition>
  <condition>Adult Children</condition>
  <condition>Hypoparathyroidism</condition>
  <condition>Hyperparathyroidism</condition>
  <condition>Pseudo Hypoparathyroidism</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood sample for circulating autotaxin measurement (5ml).</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from 10 to 18 years old :&#xD;
&#xD;
          1. Fibrous dysplasia / McCune-Albright syndrome,&#xD;
&#xD;
          2. hypoparathyroïdism,&#xD;
&#xD;
          3. hyperparathyroïdism,&#xD;
&#xD;
          4. iPPSD, from References Centers for rare diseases (Calcium and phosphate metabolism,&#xD;
             constitutional bone diseases) at hôpital Femme Mère Enfant (Bron) and at hôpital&#xD;
             Bicêtre Paris Saclay (Paris).&#xD;
&#xD;
        Adults with Fibrous dysplasia / McCune-Albright syndrome from reference center for&#xD;
        constitutional bone diseases at hôpital Edouard Herriot (Lyon).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Pediatric patients :&#xD;
&#xD;
          -  Children from 10 to 18 years old&#xD;
&#xD;
          -  Patients with Fibrous dysplasia / McCune-Albright syndrome,hypoparathyroïdism,&#xD;
             hyperparathyroïdism, or iPPSD, from References Centers for rare diseases (Calcium and&#xD;
             phosphate metabolism, constitutional bone diseases) followed at hôpital Femme Mère&#xD;
             Enfant (Bron) or at hôpital Bicêtre Paris Saclay (Paris).&#xD;
&#xD;
          -  Patients and parent / holder of parental authority who have been informed of the study&#xD;
             and do not object to participate&#xD;
&#xD;
             • Adults:&#xD;
&#xD;
          -  Patients &gt; 18 years old&#xD;
&#xD;
          -  Patients with Fibrous dysplasia / McCune-Albright syndrome, followed in reference&#xD;
             center for constitutional bone diseases at hôpital Edouard Herriot (Lyon)&#xD;
&#xD;
          -  Patients who have been informed of the study and do not object to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children &lt; 8 kg&#xD;
&#xD;
          -  Patient with hepatic disease&#xD;
&#xD;
          -  Patients under tutorship or curatorship&#xD;
&#xD;
          -  Pregnant and / or breastfeeding woman&#xD;
&#xD;
          -  Patient deprived of liberty&#xD;
&#xD;
          -  Patient in emergency situation who can not agree to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BACCHETTA Justine, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Référence des Maladies Rares du Calcium et du Phosphate</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BACCHETTA Justine, Pr</last_name>
    <phone>4 27 85 61 30</phone>
    <phone_ext>+33</phone_ext>
    <email>justine.bacchetta@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FLAMMIER Sacha, PhD</last_name>
    <phone>4 72 68 13 49</phone>
    <phone_ext>+33</phone_ext>
    <email>sacha.flammier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de compétence des maladies rares de l'insulino-sécrétion et de l'insulino-sensibilité</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NICOLINO Marc, MD PhD</last_name>
      <phone>4 27 86 92 17</phone>
      <phone_ext>+33</phone_ext>
      <email>marc.nicolino@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de référence Dysplasie Fibreuse des os Service rhumatologie et pathologie osseuse Hôpital Edouard Herriot, Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHAPURLAT Roland, MD PhD</last_name>
      <phone>4 72 11 25 02</phone>
      <phone_ext>+33</phone_ext>
      <email>roland.chapurlat@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate Service d'Endocrinologie et Diabète de l'Enfant Hôpital Bicêtre Paris Saclay</name>
      <address>
        <city>Paris</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LINGLART Linglart, MD, PhD</last_name>
      <phone>1 45 21 78 31</phone>
      <phone_ext>+33</phone_ext>
      <email>agnes.linglart@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibrous dysplasia / McCune-Albright syndrome, hypoparathyroidism, hyperparathyroidism, iPPSD, autotaxin, GNAS, PTH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrous Dysplasia of Bone</mesh_term>
    <mesh_term>Fibrous Dysplasia, Polyostotic</mesh_term>
    <mesh_term>Pseudohypoparathyroidism</mesh_term>
    <mesh_term>Pseudopseudohypoparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

